An observational study conducted on the elderly diabetes patients provided sufficient evidence that treatment with the ‘anti diabetic rosiglitazone’ is associated with an increased risk for ‘ischemic cardiovascular events’ as well as heart failure and death.
The research study was conducted at ‘Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada’, by Lorraine Lipscombe and colleagues. Results of this study were published in the “Journal of the American Medical Association”. This new study has now boiled up the ongoing heated debate over safety and labeling of ‘thiazolidinediones’.
Lorraine Lipscombe and colleagues studied the outcomes of almost 160,000 diabetes patients with more than 66 years and over age group who were treated with at least one ‘oral hypoglycemic agent’ between a period of 2002 and 2005, using health care databases for Ontario.
